Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Codexis, Nestle Health Science team up in metabolic diseases

Executive Summary

Codexis Inc. granted Nestle Health Science SA an option to license exclusive worldwide development and commercialization rights to its CDX6114 for phenylketonuria (PKU). Nestle also receives access to Codexis' CodeEvolver protein engineering platform for use in discovering therapies for other metabolic disorders and for the development of enzyme products for Nestle's medical nutrition and consumer care businesses.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies